CLINICAL_TRIALS
trial_result
· 2021-09-08
Clinical Trial Update: Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer [Phase 2]
Summary
Phase 2 trial evaluating SAR566658 in CA6-positive metastatic triple-negative breast cancer has been terminated; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-09-08